Last reviewed · How we verify
NCT04218773: PRESS
A Single Center, Pilot Study of Induced Hypertension for Minimizing Infarct Progression in Patients With Acute Large-vessel Occlusion Ischemic Stroke Undergoing Endovascular Therapy
EARLY_PHASE1 trial testing Phenylephrine in Ischemic Stroke in 40 participants. Suspended.
1 August 2026
Quick facts
| Lead sponsor | Yale University |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Suspended |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 11 September 2020 |
| Primary completion | 1 August 2026 |
| Estimated completion | 1 August 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Phenylephrine (phenylephrine) — full drug profile →
- Norepinephrine (NOREPINEPHRINE) — full drug profile →
Conditions studied
- Ischemic Stroke — all drugs for Ischemic Stroke →
- Blood Pressure — all drugs for Blood Pressure →
Sponsor
Yale University
Who can join
18 and older, any sex, with Ischemic Stroke or Blood Pressure. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Primary Feasibility Outcome: Ability to achieve and maintain systolic blood pressure goals
Time frame: Through completion of the thrombectomy procedure, an average of 2.5 hours
Percentage of treatment success is defined as the percentage of patients able to achieve target blood pressure within 60 minutes and maintain it throughout the procedure. -
Primary Safety Outcome: Number of patients with symptomatic intracranial hemorrhage
Time frame: 72 hours
Symptomatic intracerebral hemorrhage (sICH) is defined per SITS-MOST criteria as local or remote parenchymal hemorrhage type 2 on the post-treatment imaging scan, combined with a neurological deterioration of 4 points or more on the NIHSS from baseline, or from the lowest NIHSS value between baseline and 24 h, or leading to death.
Sponsor's own description
An open label, prospective, single center, pilot trial to assess feasibility and tolerability of short term blood pressure augmentation to minimize infarct progression in acute LVO stroke patients undergoing endovascular therapy.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Management of Elevated Blood Pressure After Stroke Thrombectomy for Anterior Circulation.
Wu K, Xiong Z, Ding Y. · · 2021 · cited 5× · PMID 33568958 · DOI 10.2147/rmhp.s285316
Verify or expand the search:
- PubMed search for NCT04218773
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Phenylephrine
Trials testing the same drug.
- NCT06648850 — Clinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-Growth · Phase 2, PHASE3 · not yet recruiting
- NCT06158035 — ED90 of Norepinephrine and Phenylephrine Boluses Under Intensive Treatment in Preeclamptic Patients · NA · unknown
- NCT07033845 — Pharmacokinetic Study of Topical Phenylephrine · EARLY_PHASE1 · recruiting
- NCT06158009 — ED90 of Norepinephrine and Phenylephrine Boluses Under Intensive Treatment · NA · unknown
- NCT06508359 — Norepinephrine and Phenylephrine for Spinal Anesthesia-induced Hypotension. · NA · not yet recruiting
Other recruiting trials for Ischemic Stroke
Currently open trials in the same condition.
- NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting
- NCT07375953 — Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK) · Phase 2 · recruiting
- NCT07375966 — Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours · Phase 2 · recruiting
- NCT07491952 — Continuous Dual Aspiration Technique With Zoom System for Stroke · recruiting
- NCT07371455 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LWP779 in Healthy Participants · Phase 1 · recruiting
Other Yale University trials
Trials by the same sponsor.
- NCT06900998 — Pilot Study: Effects of Nimodipine on Alcohol Drinking · Phase 2 · not yet recruiting
- NCT04910984 — Developing a Chatbot to Promote HIV Testing · NA · not yet recruiting
- NCT07458087 — Accuracy of the Accuro 3S · NA · not yet recruiting
- NCT07398404 — A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Pa · Phase 1, PHASE2 · not yet recruiting
- NCT07305324 — Improving Liver Fibrosis Diagnosis in Primary Care Using FibroX AI · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04218773 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Yale University
- Last refreshed: 27 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04218773.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing